Abbott
US Last updated 30 May 2026
- Devices
- 703
- Registries
- EUDAMEDGUDIDFDA 510(k)FDA
- FDA recalls
- 4116 ongoing
Catalogue
AlinIQ 03R8968 Ref 03R8968
Alinity 04T991A Ref 04T991A
Alinity 04T993A Ref 04T993A
Alinity 04U001A Ref 04U001A
Alinity 09P2625 Ref 09P2625
Alinity 09P2635 Ref 09P2635
Alinity 04W211A Ref 04W211A
Alinity 04W021A Ref 04W021A
Alinity 06T7901 Ref 06T7901
Alinity 06T7910 Ref 06T7910
Alinity 06T7921 Ref 06T7921
Alinity 08P4321 Ref 08P4321
Alinity 06T7931 Ref 06T7931
Alinity 04T851B Ref 04T851B
Alinity 04T855B Ref 04T855B
Alinity 04T853B Ref 04T853B
Alinity 04T857B Ref 04T857B
Alinity 06T321A Ref 06T321A
Alinity 06T793A Ref 06T793A
Alinity 09P261D Ref 09P261D
Amplatzer TorqVue LP Delivery System Ref K261825
Architect 6L23-01 Ref 6L23-01
Architect 7D73-22 Ref 7D73-22
Architect 02K4524 Ref 02K4524
Alinity 09P5920 Ref 09P5920
Alinity 08P6101 Ref 08P6101
Alinity 07P8401 Ref 07P8401
Alinity 04Z231A Ref 04Z231A
Architect 3L79-32 Ref 3L79-32
Alinity 08P361A Ref 08P361A
Alinity 08P5620 Ref 08P5620
Architect 3P24-25 Ref 3P24-25
Alinity 07P4540 Ref 07P4540
Architect 2K98-03 Ref 2K98-03
Architect 06P2237 Ref 06P2237
Alinity 04T811A Ref 04T811A
FIRMap AR064050 Ref AR064050
Architect 08K2529 Ref 08K2529
Alinity 08P021A Ref 08P021A
Alinity 09P341A Ref 09P341A
Architect 6L22-10 Ref 6L22-10
Alinity 08P321A Ref 08P321A
Alinity 07P921A Ref 07P921A
Alinity 07P981A Ref 07P981A
Alinity 06P0850 Ref 06P0850
Alinity 07P6801 Ref 07P6801
Alinity 01R141A Ref 01R141A
Alinity 06R901A Ref 06R901A
Alinity 04U7501 Ref 04U7501
Alinity 03R751A Ref 03R751A
Showing 1-50 of 703
FDA recalls
2026
- 10 Sep 2026 Z-0191-2027 Not yet classified Ongoing Changes to Instructions for Use (IFU) for the device regarding risk of Pulmonary Artery Injury (PAI).
2025
- 10 Sep 2025 Z-0109-2026 Class I Ongoing Abbott has become aware of a limited number of tip detachment events during catheter removal from the packaging.
- 10 Sep 2025 Z-0110-2026 Class I Ongoing Abbott has become aware of a limited number of tip detachment events during catheter removal from the packaging.
- 10 Sep 2025 Z-0111-2026 Class I Ongoing Abbott has become aware of a limited number of tip detachment events during catheter removal from the packaging.
- 10 Sep 2025 Z-0112-2026 Class I Ongoing Abbott has become aware of a limited number of tip detachment events during catheter removal from the packaging.
- 10 Sep 2025 Z-0113-2026 Class I Ongoing Abbott has become aware of a limited number of tip detachment events during catheter removal from the packaging.
- 17 Mar 2025 Z-1643-2025 Class II Ongoing Device may have a small breach in the proximal end of the shaft under the strain relief of the delivery system. Breach is not visibly detectable and may lead to prolonged procedure, blood loss, or air ingress with potential for air embolism.
- 17 Mar 2025 Z-1644-2025 Class II Ongoing Device may have a small breach in the proximal end of the shaft under the strain relief of the delivery system. Breach is not visibly detectable and may lead to prolonged procedure, blood loss, or air ingress with potential for air embolism.
2024
- 4 Mar 2024 Z-1479-2024 Class II Ongoing Customer complaints were received regarding falsely elevated results for some patient samples. Internal studies with customer return samples confirmed potential interactions that may lead to falsely elevated results when processed as below on the same instrument: " ARCHITECT Syphilis TP (LN 8D06) and/or ARCHITECT AdviseDx SARS-CoV-2-IgG II (LN 6S60) precedes ARCHITECT Anti-HCV testing (LN 1L79). " Alinity i Syphilis TP (LN 07P60) precedes Alinity i Anti-HCV testing (LN 08P05).
- 4 Mar 2024 Z-1480-2024 Class II Ongoing Customer complaints were received regarding falsely elevated results for some patient samples. Internal studies with customer return samples confirmed potential interactions that may lead to falsely elevated results when processed as below on the same instrument: " ARCHITECT Syphilis TP (LN 8D06) and/or ARCHITECT AdviseDx SARS-CoV-2-IgG II (LN 6S60) precedes ARCHITECT Anti-HCV testing (LN 1L79). " Alinity i Syphilis TP (LN 07P60) precedes Alinity i Anti-HCV testing (LN 08P05).
Show the 25 most recent of 41 recalls
2023
- 28 Sep 2023 Z-0209-2024 Class II Ongoing Certain NT2000iX RF generators were serviced using a tool that was subsequently found to be out of tolerance and therefore may not have provided accurate results for potential capacitance failure.
- 12 Jun 2023 Z-2110-2023 Class I Ongoing There is an overall reported incidence rate of 0.77% related to observed or potential air embolism during procedures in which the ASDS product was used.
2022
- 9 Jun 2022 Z-1344-2022 Class II Terminated When connected to the EnSite Precision Navigation System, an affected TactiCath Contact Force Ablation Catheter, Sensor Enabled may present the error message: "invalid catheter,, or "expired catheter."
- 28 Apr 2022 Z-1213-2022 Class II Terminated Incorrect product labeling.
- 24 Mar 2022 Z-0956-2022 Class II Terminated Devices were manufactured with a "First Use Date" preprogrammed in the EEPROM which disables the use of the single-use device.
- 24 Mar 2022 Z-0957-2022 Class II Terminated Devices were manufactured with a "First Use Date" preprogrammed in the EEPROM which disables the use of the single-use device.
2021
- 16 Nov 2021 Z-0420-2022 Class II Terminated As a result of a manufacturing error, one (1) lot of Ultimum Hemostasis Introducer devices was manufactured with an incorrect hub and overall length. The devices manufactured were 12 cm in length instead of the intended 5 cm in length.
- 9 Nov 2021 Z-0895-2022 Class II Terminated Instructions for use were updated.
2020
- 19 Jun 2020 Z-2701-2020 Class II Terminated Quality Control results were not properly evaluated for QC failures.
- 22 May 2020 Z-2541-2020 Class II Terminated High rate of reported complaints for the loss of contact force information while using the TactiCath Quartz Contact Force Ablation Catheter
- 12 May 2020 Z-2401-2020 Class II Terminated There is a potential to generate incorrect patient results for the following assays: Alkaline Phosphatase, Amylase, Creatine Kinase, and Gamma Glutamyl Transferase.
- 24 Apr 2020 Z-2117-2020 Class II Ongoing Abbott identified that samples tested for ARCHITECT STAT High Sensitive Troponin I and STAT High Sensitivity Troponin I assays (LN 3P25 and LN 2R98) may show interaction when processed directly after the ARCHITECT iGentamicin (LN 1P31) assay and patient results might be impacted.
- 9 Mar 2020 Z-1728-2020 Class II Terminated An erroneous concentration value for hepatitis A virus was utilized during manufacture, leading to a decreased amount of antigen used for the impacted lots.
- 28 Feb 2020 Z-1700-2020 Class II Terminated Internal testing of software identified software anomaly scenarios where if non-applicable shock energy value is selected, the device will continue to use the previously programmed energy level and the user will not be alerted that the selected value was not retained.
- 24 Jan 2020 Z-1580-2020 Class II Terminated Abbott has identified potential performance issues for the Alinity ci -series Software version 2.6.2 and earlier.
FDA establishments
- ABBOTT GmbH Wiesbaden Hesse · DE FEI 3002809144
What Abbott makes
The company produces in vitro diagnostic (IVD) laboratory instruments and software, including analysers for spectrophotometry and chemiluminescent immunoassays, as well as related reagents and kits for testing hepatitis A, hepatitis B, and gamma-glutamyltransferase (GGT). It also manufactures single-use cardiac mapping catheters for percutaneous procedures and buffered sample diluents for diagnostic use, alongside glucose and carbon dioxide (CO₂) testing kits.
These products are regulated under Class I and Class II classifications in the US, with some devices exempt from classification (N). They are listed in the FDA’s Unique Device Identifier (UDI) database, reflecting their authorised status for commercial distribution in the United States.
Information
- Country
- US
- Website
- abbott.com
- [email protected]
- Phone
- +1(650)681-3470
- DUNS number
- 080174723